We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs
News

deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs

deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs
News

deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

deCODE chemistry & biostructures has announced the initiation of a collaboration with UCB. Under the terms of the deal, deCODE and UCB will collaborate on the structure-based discovery of small molecule modulators of undisclosed cytokine targets.

The program will focus on integrated structure-based drug design leveraging deCODE’s Fragments of Life™ technology for lead identification and optimization. As the program advances, it may also capitalize on deCODE's expertise in ADMET and PK/PD.  The financial terms of the research fee, milestone and royalty-bearing relationship were not disclosed.
Advertisement